Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain

被引:129
作者
Chowdhury, Sultan [1 ]
Chafeev, Mikhail [1 ]
Liu, Shifeng [1 ]
Sun, Jianyu [1 ]
Raina, Vandna [1 ]
Chui, Ray [2 ]
Young, Wendy [2 ]
Kwan, Rainbow [2 ]
Fu, Jianmin [1 ]
Cadieux, Jay A. [1 ]
机构
[1] Xenon Pharmaceut Inc, Dept Med Chem, Burnaby, BC V5G 4W8, Canada
[2] Xenon Pharmaceut Inc, Dept Biol Sci, Burnaby, BC V5G 4W8, Canada
关键词
Sodium channel; SCN9A; Pain; Spirooxindole; Oxindole; GATED SODIUM-CHANNELS; MUTATIONS; SCN9A; PHARMACOLOGY; TARGETS; POTENT; FURAN;
D O I
10.1016/j.bmcl.2011.04.088
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Starting from the oxindole 2a identified through a high-throughput screening campaign, a series of Na(V)1.7 blockers were developed. Following the elimination of undesirable structural features, preliminary optimization of the oxindole C-3 and N-1 substituents afforded the simplified analogue 9b, which demonstrated a 10-fold increase in target potency versus the original HTS hit. A scaffold rigidification strategy then led to the discovery of XEN907, a novel spirooxindole Na(V)1.7 blocker. This lead compound, which in turn showed a further 10-fold increase in potency, represents a promising structure for further optimization efforts. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3676 / 3681
页数:6
相关论文
共 25 条
[1]  
[Anonymous], 2009, Curr. Bioact. Compd., DOI [10.2174/157340709787580900, DOI 10.2174/157340709787580900]
[2]  
Brueckner C., 1988, J ORG CHEM, V53, P2450
[3]   International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels [J].
Catterall, WA ;
Goldin, AL ;
Waxman, SG .
PHARMACOLOGICAL REVIEWS, 2005, 57 (04) :397-409
[4]   An SCN9A channelopathy causes congenital inability to experience pain [J].
Cox, James J. ;
Reimann, Frank ;
Nicholas, Adeline K. ;
Thornton, Gemma ;
Roberts, Emma ;
Springell, Kelly ;
Karbani, Gulshan ;
Jafri, Hussain ;
Mannan, Jovaria ;
Raashid, Yasmin ;
Al-Gazali, Lihadh ;
Hamamy, Henan ;
Valente, Enza Maria ;
Gorman, Shaun ;
Williams, Richard ;
McHale, Duncan P. ;
Wood, John N. ;
Gribble, Fiona M. ;
Woods, C. Geoffrey .
NATURE, 2006, 444 (7121) :894-898
[5]   Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy [J].
Cummins, TR ;
Dib-Hajj, SD ;
Waxman, SG .
JOURNAL OF NEUROSCIENCE, 2004, 24 (38) :8232-8236
[6]   Sodium Channels in Normal and Pathological Pain [J].
Dib-Hajj, Sulayman D. ;
Cummins, Theodore R. ;
Black, Joel A. ;
Waxman, Stephen G. .
ANNUAL REVIEW OF NEUROSCIENCE, VOL 33, 2010, 33 :325-347
[7]  
England S, 2008, EXPERT OPIN INV DRUG, V17, P1849, DOI [10.1517/13543780802514559, 10.1517/13543780802514559 ]
[8]   SCN9A mutations in paroxysmal extreme pain disorder:: Allelic variants underlie distinct channel defects and phenotypes [J].
Fertleman, Caroline R. ;
Baker, Mark D. ;
Parker, Keith A. ;
Moffatt, Sarah ;
Elmslie, Frances V. ;
Abrahamsen, Bjarke ;
Ostman, Johan ;
Klugbauer, Norbert ;
Wood, John N. ;
Gardiner, R. Mark ;
Rees, Michele .
NEURON, 2006, 52 (05) :767-774
[9]   Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations [J].
Goldberg, Y. P. ;
MacFarlane, J. ;
MacDonald, M. L. ;
Thompson, J. ;
Dube, M-P ;
Mattice, M. ;
Fraser, R. ;
Young, C. ;
Hossain, S. ;
Pape, T. ;
Payne, B. ;
Radomski, C. ;
Donaldson, G. ;
Ives, E. ;
Cox, J. ;
Younghusband, H. B. ;
Green, R. ;
Duff, A. ;
Boltshauser, E. ;
Grinspan, G. A. ;
Dimon, J. H. ;
Sibley, B. G. ;
Andria, G. ;
Toscano, E. ;
Kerdraon, J. ;
Bowsher, D. ;
Pimstone, S. N. ;
Samuels, M. E. ;
Sherrington, R. ;
Hayden, M. R. .
CLINICAL GENETICS, 2007, 71 (04) :311-319
[10]   REACTION OF [METHOXY(PHENYLTHIO)METHYL]TRIMETHYLSILANE WITH ARENES AND ALK-1-ENES IN THE PRESENCE OF LEWIS ACID [J].
HAN, DI ;
OH, DY .
SYNTHETIC COMMUNICATIONS, 1989, 19 (11-12) :2213-2218